1-Piperazineethanamine, N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- manufacturers
- ZZW-115
-
- $182.00 / 1mg
-
2026-02-03
- CAS:801991-87-7
- Min. Order:
- Purity: 99.17%
- Supply Ability: 10g
|
| | 1-Piperazineethanamine, N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- Basic information |
| | 1-Piperazineethanamine, N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- Chemical Properties |
| storage temp. | Store at -20°C |
| | 1-Piperazineethanamine, N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- Usage And Synthesis |
| Uses | ZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. Anticancer activity[1][2]. | | Biological Activity | ZZW-115 is a potent NUPR1 inhibitor with Kd of 2.1 μM, which induces tumor cell death via necrosis and apoptosis. Has anticancer activity. | | in vitro | ZZW-115 (0.1-33 μM; 72 hours) is efficient in killing cancer cells, with an IC 50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14 ).
ZZW-115 (0-100 μM; 24-72 hours) is efficient to kill these tumor cells with an IC 50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).
ZZW-115 induces pancreatic cell death by necrosis and apoptosis. ZZW-115 treatment induces a decrease in ATP production and induces a ROS overproduction.
LDH release is significantly higher in ZZW-115-treated cells (MiaPaCa-2, 02-063, LIPC, Foie8b, and HN14 cells) than in control cells in a concentration-dependent manner. Similarly, caspase 3/7 activity is also greater in ZZW-115-treated cells. These experiments demonstrated that ZZW-115 exerted both pronecrotic and proapoptotic effects. Cell Viability Assay | Cell Line: | ANOR cells, MiaPaCa-2, 02-063, 01008, LIPC, 02136, HN01,01046, AOIPC, Foie8b, HN14 cells | < /tr> | Concentration: | 0.1- 33 μM | | Incubation Time: | 72 hours | | Result: | Was efficient in killing cancer cells, with an IC 50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14). | Cell Proliferation Assay | Cell Line: | U87, A375, U2OS, SaOS-2, HT29, SK-CO-1, LS174T, H1299 and H358, HepG2, PC3, THP-1, Daudi, Jurkat and MDA-MB-231 cells | | Concentration: | 0-100 μM | | Incubation Time: | 24 or 72 hours | | Result: | Was efficient to kill these tumor cells with an IC 50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM ( SaOS-2 cells). | | | in vivo | ZZW-115 (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors.
ZZW-115 (5 mg/kg for 30 days; immunocompetent C57BL /6 mice were orthotopically implanted with Panc02 cells) treatment showed the tumor size is almost unmeasurable in some cases. | Animal Model: | NMRI -Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells | | Dosage: | 5 , 2.5, 1.0, or 0.5 mg/kg | | Administration: | Injection, daily for 30 days | | Result: | When the mice were injected with 5 mg/kg, the tumors stopped growing a few days after treatment and their size decreased progressively, almost disappearing at the end of the treatm ent. | | | References | [1] Santofimia-Castao P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. DOI:10.1172/JCI127223
[2] Santofimia-Castao P, et al. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Cells. 2019;8(11):1453. Published 2019 Nov 17. DOI:10.3390/cells8111453 |
| | 1-Piperazineethanamine, N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- Preparation Products And Raw materials |
|